clopidogrel and Bradycardia

clopidogrel has been researched along with Bradycardia in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aikawa, H; Etou, H; Inoue, R; Kazekawa, K; Kureshima, M; Matsumoto, Y; Narita, S; Nii, K; Sakamoto, K; Tsutsumi, M; Yoshida, H1
Dong, C; Liu, X; Ren, C; Ren, Q; Zhang, X1
Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; James, S; Katus, H; Michelson, EL; Pais, P; Raev, D; Scirica, BM; Spinar, J; Steg, PG; Storey, RF; Wallentin, L1

Trials

2 trial(s) available for clopidogrel and Bradycardia

ArticleYear
Cilostazol reduces periprocedural hemodynamic depression in carotid artery stenting.
    Neurologia medico-chirurgica, 2013, Volume: 53, Issue:3

    Topics: Aged; Angioplasty; Bradycardia; Carotid Stenosis; Cilostazol; Clopidogrel; Female; Humans; Hypotension; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Tetrazoles; Ticlopidine

2013
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiogr
    Journal of the American College of Cardiology, 2011, May-10, Volume: 57, Issue:19

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Bradycardia; Clopidogrel; Electrocardiography; Female; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome

2011

Other Studies

1 other study(ies) available for clopidogrel and Bradycardia

ArticleYear
Ticagrelor vs. clopidogrel in non-ST-elevation acute coronary syndromes.
    Herz, 2016, Volume: 41, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Bradycardia; Clopidogrel; Comorbidity; Electrocardiography; Female; Germany; Humans; Male; Non-ST Elevated Myocardial Infarction; Prevalence; Purinergic P2Y Receptor Antagonists; Risk Factors; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome

2016